Analyzing Unity Biotechnology (UBX) & The Competition

Unity Biotechnology (NASDAQ:UBX – Get Rating) is one of 976 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Unity Biotechnology to similar companies based on the strength of its analyst recommendations, profitability, risk, earnings, valuation, dividends and institutional ownership.

Earnings & Valuation

This table compares Unity Biotechnology and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Unity Biotechnology	$4.78 million	-$60.72 million	-0.53
Unity Biotechnology Competitors	$1.82 billion	$246.33 million	-6.63

Unity Biotechnology’s rivals have higher revenue and earnings than Unity Biotechnology. Unity Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Unity Biotechnology has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Unity Biotechnology’s rivals have a beta of 0.84, indicating that their average stock price is 16% less volatile than the S&P 500.

Insider and Institutional Ownership

40.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.6% of Unity Biotechnology shares are owned by insiders. Comparatively, 15.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Unity Biotechnology and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0	0	5	0	3.00
Unity Biotechnology Competitors	3740	14297	40388	681	2.64

Unity Biotechnology presently has a consensus target price of $34.00, indicating a potential upside of 721.26%. As a group, “Pharmaceutical preparations” companies have a potential upside of 107.90%. Given Unity Biotechnology’s stronger consensus rating and higher possible upside, analysts clearly believe Unity Biotechnology is more favorable than its rivals.

Profitability

This table compares Unity Biotechnology and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-98.71%	-47.93%
Unity Biotechnology Competitors	-3,334.66%	-179.78%	-35.60%

Summary

Unity Biotechnology rivals beat Unity Biotechnology on 7 of the 13 factors compared.

Unity Biotechnology Company Profile

(Get Rating)

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.